ClinicalTrials.gg
RecruitingNCT04935164TRANSIDENTUpdated Oct 23, 2026

Comparative Study of Gender Identity Disorder Versus Control

An observational study in Gender Dysphoria, Adult, sponsored by Centre Hospitalier Henri Laborit. Recruiting at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre Hospitalier Henri Laborit · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Gender Dysphoria with a site in France — 3 open to participants now, 3 under way, 1 of them phase 3. Gender Dysphoria · France.

Planned enrollment
5th of 10
120 · median 110
Started
2021
with 2 others
Observational
10 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Centre Hospitalier Henri Laborit

Among the 11 studies in Gender Dysphoria with a site in France, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2021, is one of 10 observational ones, and was the 7th registered.

Gender Dysphoria

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

Browse Gender Dysphoria studies →

Open to participants now

3 of the 11 studies in Gender Dysphoria with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Gender Dysphoria with a site in France, or all of them as a file.
02

Study summary

Gender dysphoria is manifested by an internal tension between biological sex and gender, that is, by a non-congruence, in the subjects who suffer from it, between their sex of birth and their social gender identity.

Read the detailed description

Gender dysphoria is manifested by an internal tension between biological sex and gender, that is, by a non-congruence, in the subjects who suffer from it, between their sex of birth and their social gender identity. Gender dysphoria is accompanied by the often overwhelming need for a hormonal or even hormone-surgical transition. Gender dysphoria is very often characterized by fluctuating mood sadness, irritability, obsessionality. An improvement in the quality of life after medical treatment (hormone therapy) and gender reassignment surgery has been described in the literature. Morphological similarities have been found between the brains of women and the brains of so-called transgender women, as well as between the brains of transgender men and men. These morphological data are only very fragmentary and have not been supported by neuro-functional data. Self-awareness, which refers to the awareness that an individual has of his body, his image and his own identity, is partly underpinned, at the brain level, by the activation of the Default Mode Network (DMN) at rest, in non-pathological conditions. The conflict between the internal perception of the own body and its objective representation could result in a change in brain connectivity within the DMN, due in particular to changes in the activation of the temporo parietal junction.

03

Conditions studied

  • Gender Dysphoria, Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Contact sponsor for more details

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with gender dysphoria
  • Without psychotropic
  • Without hormono-therapy
  • Without sexual surgery assignation

Exclusion criteria

Exclusion Criteria:

  • Any depression
  • Any addiction
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Male patients with gender dysphoria

    * male patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation * patients without psychotropic treatments * patients who do not benefit of hormone therapy * patients who have not yet received gender reassignment surgery * patients aged 18 to 60 years * patients with normal or corrected vision * patients without mental defect * patients without neurological impairment

    Other: Psychiatric evaluations

  • Female patients with gender dysphoria

    * female patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation * patients without psychotropic treatments * patients who do not benefit of hormone therapy * patients who have not yet received gender reassignment surgery * patients aged 18 to 60 years * patients with normal or corrected vision * patients without mental defect * patients without neurological impairment

    Other: Psychiatric evaluations

  • Male volunteers without gender dysphoria

    * male volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation * volunteer aged 18 to 60 years * volunteer with normal or corrected vision * volunteer without mental defect * volunteer without neurological impairment

    Other: Psychiatric evaluations

  • Female volunteers without gender dysphoria

    * female volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation * volunteer aged 18 to 60 years * volunteer with normal or corrected vision * volunteer without mental defect * volunteer without neurological impairment

    Other: Psychiatric evaluations

Interventions

  • OtherPsychiatric evaluations

    At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes

    Also known as: Electroencephalography, Double Mirror Test, Mini International Neuropsychiatric Interview, Montgomery-Åsberg Depression Rating Scale, Hamilton Rating Scale for Depression

06

What researchers measure

Primary outcomes

  1. Contribution of temporal parameters of microstates C, D, E and F

    The proportion of the total time spent in microstates of class C,D,E and F

    Time frame: Week 1 to Week 24

  2. Duration of temporal parameters of microstates C, D, E and F

    Time frame: Week 1 to Week 24

  3. Mean-Global Field Power temporal parameters of microstates C, D, E and F

    Time frame: Week 1 to Week 24

  4. Occurrence of temporal parameters of microstates C, D, E and F

    Time frame: Week 1 to Week 24

  5. Cortical voxel activity from source reconstruction analysis, using electroencephalogram during Double Mirror Test (D.M.T).

    Time frame: Week 1 to Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Mar 2029, 96 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Jun 22, 2021
StartActual
Mar 26, 2021
Primary completionEst.
Mar 2029
CompletionEst.
Dec 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details, site details and index terms
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 4 other changes: verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04935164
Lead sponsor
Centre Hospitalier Henri Laborit
Responsible party
Sponsor
First posted
Jun 22, 2021
Start date
Mar 26, 2021
Primary completion
Mar 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Bérangère Thirioux, PhD
Contact
berangere.thirioux@ch-poitiers.fr
0033 5 49 44 58 56

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion